MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma
Condition: Metastatic NRAS Melanoma Interventions: Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1); Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2); Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3) Sponsor: Hospices Civils de Lyon Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Hydroxychloroquine | Melanoma | Neuroblastoma | Neurology | Research | Skin Cancer